Corcept Therapeutics Incorporated (CORT) — Stock Score Summary

Corcept Therapeutics Incorporated (CORT) has a MoatMap StockRank of 75/100 based on Quality (71/100), Value (32/100), and Momentum (54/100) factor scores. The current signal is BUY. Corcept Therapeutics is a specialty pharma company heavily reliant on a single product (Korlym) and faces significant ongoing patent litigation, making it too risky for our high-conviction portfolio.

Corcept Therapeutics Incorporated is a pharmaceutical company specializing in the discovery and development of cortisol-modulating drugs, with Korlym approved for Cushing's syndrome. The company establishes a strong market position by addressing rare diseases with proprietary treatments. This niche focus and pipeline of selective cortisol modulators provide a competitive edge.

Key Financial Metrics

Price$74.89
Market Cap$7.3B
P/E (TTM)213.97
P/E (Forward)30.02
Price/Book12.60
Return on Equity7.2%
Return on Invested Capital6.7%
Debt/Equity1.51
Gross Margin98.3%
Operating Margin-30.1%
Revenue Growth4.9%
Free Cash Flow$116M

Corcept Therapeutics Incorporated operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Corcept Therapeutics Incorporated’s (CORT) StockRank?
MoatMap’s StockRank for Corcept Therapeutics Incorporated (CORT) is 75/100, with a Buy signal. It is a composite of Quality (71), Value (32), and Momentum (54) factor ranks across MoatMap’s 19,000+ stock universe.
Does Corcept Therapeutics Incorporated have an economic moat?
Corcept Therapeutics Incorporated (CORT) has a Quality factor score of 71/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Corcept Therapeutics Incorporated a buy, hold, or sell?
MoatMap’s current signal for Corcept Therapeutics Incorporated (CORT) is Buy, based on a StockRank of 75/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Corcept Therapeutics Incorporated in?
Corcept Therapeutics Incorporated (CORT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksCORT deep dive reportAI ChampionsHow we score stocksSense-check another stock